MICROGLIA AND NEUROINFLAMMATION
Microglia are mesoderm-derived brain macrophages and represent the resident immunocompetent cells of the CNS. In conditions of an intact blood-brain barrier when blood-borne cells are largely absent, microglia together with perivascular cells are the first line of the immune defense system of the brain. In response to neuronal injury or even subtle perturbations of the CNS environment, resident microglia react with a set of stereotypic changes in their physiological state. The transition of microglia into an activated state includes a change in their morphology, migration toward the site of neuronal damage, proliferation until they quadruplicate in number, and cell surface expression and release of a widespread variety of proinflammatory molecules. If cell death occurs, activated microglia mature into full-blown macrophages. 1 This responsiveness of microglia to a wide variety of pathological stimuli has led to their description as a "sensor for pathological events in the CNS." peripheral nerve injury. 6, 7 The general concept of microglial activation has been extensively reviewed with respect to its potential relevance for cytotoxicity, 8, 9 plasticity, 7 and inflammation and site-directed homing of inflammatory cells to areas containing activated microglia. 10 More comprehensive data looking at the full complement of activation-induced genes in microglia have now also become available. 11, 12 Here, we outline the rational for studying in vivo activated microglia by using brain positron emission tomography (PET). The in vivo detection of activated microglia may serve as a surrogate marker of neuronal damage, CNS disease activity, and, more speculatively, brain plasticity. 13 
PET IMAGING OF THE PERIPHERAL BENZODIAZEPINE RECEPTOR

Cellular source and function
The peripheral benzodiazepine receptor (PBR) is a hetero-oligomeric complex, that appears to be largely, though not exclusively, localized in the outer membrane of mitochondria. 14, 15 However, there is also disproportionately high binding to nonmitochondrial fractions of brain extract and mitochondria-free cells.
14, 16 The name derives from the binding of certain benzodiazepines, such as diazepam, to this receptor, which is distinct from the central benzodiazepine receptor associated GABA Aregulated channels. Other names have also been used such as mitochondrial benzodiazepine receptor and peripheral benzodiazepine binding site.
In the CNS, the PBR is exclusively found on non-neuronal cells, primarily activated microglia or, in the case of a disrupted blood-brain barrier, on invading cells of mononuclear-phagocyte lineage. [17] [18] [19] Early studies of the functional role of the PBR were performed in astrocytes cell cultures, which express high levels of PBR in vitro. 20 As will be discussed shortly, however, these in vitro observations could not be fully extended to the in vivo state. 18 -20 Differences in the functional behavior of cells between the in vivo and in vitro state are not unusual. For example, although astrocytes in vivo show hypertrophy in response to brain disease, they generally do not proliferate, whereas in vitro they have a high proliferation rate. In contrast, microglia proliferate both in vitro and in vivo.
Given that the PBR is closely linked to cell cycle control, 22, 23 this obvious difference in the proliferative behavior of astrocytes in vitro cautions against extrapolating to conclude that astrocytic PBR expression will also occur in vivo. The PBR is not expressed significantly in normal brain parenchyma, except for low-level expression in certain areas, such as those constitutively without blood-brain barrier (i.e., the choroid plexus and the ependymal cells lining the ventricles).
The gene for the PBR is remarkably well preserved across species, implying an important housekeeping function. A role in the cerebral steroid biosynthesis and regulation of immunologic responses has been reported. 24 More recently, the term translocator protein (18 kDa) has been proposed. 25 The proposed name refers to the main molecular functions of the 18-kDa protein, namely, the binding and transport into the mitochondria of cholesterol, proteins, and porphyrin, with regulation of the steroid synthesis being the most extensively studied function.
There remains considerable lack of clarity as to whether other observed effects of purported PBR ligands (such as increasing cell survival by modulating free radical production, regulating cell-death, and promoting cell proliferation) are solely due to the 18-kDa protein. Some of these cellular effects have been seen using high doses of synthetic PBR ligands, which cause other nonspecific modulatory effects, such as the inhibition of ATP kinases. 26 Also, there is still insufficient information with regard to the existence of PBR subunits or functionally and structurally related binding sites, which would help to explain the reported differences between different PBR ligands in their cellular distribution and function.
PK11195 binding to PBR: from in vitro ligand to in vivo PET tracer
PK11195, or 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide, is a specific ligand for the PBR. It has been widely used for the functional characterization of the PBR and identification of its cellular source in brain tissue. High-resolution microautoradiography with the R-enantiomer [ 21, 27 Indeed, numerous experimental models have shown that autoradiographically detected PK11195 binding correlates better with the temporospatial profile of microglial activation than with that of reactive astrocytes. 18, 19, 28, 29 Discrepancies with other reported cellular localization data using a polyclonal antibody 30 might hint to differences between the sites or PBR subunits recognized by the antibody and those to which (R)-PK11195 binds on tissue sections and in vivo. Cellular localization data from a model of chemically induced demyelination using cuprizone reported by the same group, indicate that in certain lesion-types, astrocytes, too, bind PK11195. 31 However, the high-resolution (photoemulsion) autoradiographic binding pattern in the demyelinated areas shows a different, less dense and obvious localization of the silver grains to astrocytic processes compared with the high background signal and the high density seen on activated microglia. 32 Likewise, there is little binding of (R)-PK11195 in surgically removed tissue of hippocampal sclerosis. Where any binding has been seen, it appears to be on activated microglia lying amid the astrogliotic scar tissue. 8 Thus, most in vivo data suggest that activated microglia (in the absence of blood-borne inflammatory cells) are the dominant source of PK11195 binding in areas of active pathology. Given the much lower sensitivity with which ligand binding can be detected in vivo, and the inherent threshold in the calculation of the values of specific binding, the signal measured by [ 11 C](R)-PK11195 PET is unlikely to reflect any significant contribution by astrocytes.
Advances in kinetic modeling of PET images with PK11195
Parametric images of regional [ 11 C](R)-PK11195 binding at the voxel level have been obtained using a simplified reference tissue model 33, 34 and cluster analysis. [35] [36] [37] [38] Parametric maps of [ 11 C](R)-PK11195 binding potential were generated using a basis function implementation of a simplified reference tissue model 34 (FIG. 1) . The choice of the simplified reference tissue model reflects the empirical observation that in the case of PK11195, the use of a plasma input function is less sensitive than the calculation of parametric images using a reference tissue-derived input function. The simplified reference tissue model is expected to show a dependency on regional blood flow and underestimation of the true signal when the reference region selected is not a pure reference: that is, the a priori assumption that the region of interest (ROI) is devoid of specific binding is violated. Therefore, the often-used cerebellar reference region is not, unlike for many other ligands, well suited for the definition of the tissue input function of PK11195, because it contains significant constitutively expressed PBR and numerous relatively large blood vessels within the folia.
The possible contamination with a constitutive binding signal in a purely anatomically defined reference region is also relevant in conditions where global changes in binding may occur. Cluster analysis offers an alternative data-led approach for the extraction of the normal ligand kinetic that can serve as the reference input function. Cluster analysis allows the automatic segmentation of the dynamic raw data into a number of clusters of concentration time-activity curves (TACs) on the basis of the shape of the TAC. The process then associates each voxel of the image with one of the cluster curves according to the likelihood with which the TAC of the voxel belongs to one of the clusters.
In normal brain, the majority (ϳ90%) of the voxels are segregated into two clusters, one representing the TAC mainly from the skull and scalp, and one representing the TAC of voxels mostly located in the cerebral cortex (FIG. 2) . The latter was identified as the kinetic of the ligand in normal brain tissue. The suitability of the TAC extracted by cluster analysis as the individual normal ligand kinetic was confirmed by testing for dissimilarity with a normal population input kinetic ( 2 test Ͻ 0.95) (FIG. 2) . A normalized mean TAC (population input kinetic) was calculated from the normal ligand kinetics as previously identified by cluster analysis and cortical gray ROI in a group of normal subjects. A highly significant correlation was obtained between calculated values using the cluster analysis approach and those calculated using the reference input kinetic generated from a cerebellar ROI in a sample of images obtained from normal controls and patients affected by herpes encephalitis, a disease that spares the cerebellum. 39 The robustness of cluster analysis for the extraction of a reference tissue region for the quantification of [ 11 C](R)-PK11195 PET studies has recently been confirmed by Turkheimer et al. 40 The authors also described that an improvement in the signal to noise ratio can be achieved by a clustering algorithm that selects reference voxels avoiding regions with nonspecific binding and specific binding located in the blood vessel walls.
Although the desirable absolute quantification of PK11195 binding has not been achieved, the potential errors introduced by the cluster analytical approach have been found to be systematic across healthy and diseased subjects and thus do not affect the statistical significance of differences found between comparator groups. A trend toward a small underestimation of the true signal and thus reduced sensitivity is currently the most obvious shortcoming. It is likely that a genuine increase in sensitivity will come from the development of new PBR ligands with better pharmacokinetic properties rather than from improved tracer modeling.
IMAGING NEUROINFLAMMATION IN INFLAMMATORY BRAIN DISEASES
Multiple sclerosis
In MS, quantitative [ 11 C](R)-PK11195 PET demonstrated increased PBR expressed by activated microgliamacrophages in areas of focal pathology identified by T1-and T2-weighted MRI, and also in MRI normalappearing cerebral regions, including gray matter. 27 The overlap between areas with MRI-defined pathology and with increased [
11 C](R)-PK11195 binding reached a peak in gadolinium-enhancing lesions, in which 30% of the volume had a significant increase of [ 11 C](R)-PK11195 binding. For patients studied during an acute relapse the overlap increased in both T2-weighted hyperintense areas and also the T1 black holes with respect to MS patients not in relapse.
One patient with secondary progressive MS showed high In patients with optic neuritis, a white matter tract pathology associated with anterograde glial reactions in the projection areas of the optic nerves, increased [ 11 C](R)-PK11195 binding was found in the lateral geniculate bodies. Given that MRI did not reveal disruption of the blood-brain barrier or obvious structural abnormalities in the lateral geniculate bodies, the increased [ 11 C](R)-PK11195 binding is indicative of a subtle microglial activation secondary to the degeneration of the optic tract.
In vitro experiments using [ 3 H]PK11195 microautoradiography after peripheral axotomy demonstrated that activated [ 3 H]PK11195-binding microglial cells are also found remote from the primary lesion in regions that are connected via retrograde and anterograde neuronal projections. 21 Axotomy of the facial nerve results in an activation of microglial cells in the facial nucleus as a response to the retrograde neuronal reaction. Likewise, axotomy of the sciatic nerve induces an anterograde microglial activation in the ipsilateral nucleus gracilis, the nucleus receiving the ipsilaterally projecting fibers ascending from the dorsal root ganglion.
Rasmussen's encephalitis
Rasmussen's encephalitis is a rare progressive inflammatory brain disease clinically presenting as epilepsia partialis continua and frequently associated with hemiplegia, hemianopsia and intellectual deterioration. 41 Neuropathologically, the disease is characterized by multifocal inflammation, neuronophagia, activated microglia, microglial nodules, and brain atrophy generally confined to one cerebral hemisphere. A second pathology, such as cortical dysplasia, vascular malformations, and astrocytomas, has been found in ϳ10% of patients with Rasmussen's encephalitis. It has been suggested that Rasmussen's encephalitis may have an autoimmune origin; however, the autoimmune mechanisms and the precise role played by antibody-mediated mechanisms, T-cell immunity, and viral antigens remain unclear.
Although the peculiar anatomic restriction of the pathologic process to a single hemisphere is a consistent finding, Rasmussen and others have noted that a "chronic encephalitis" can frequently be seen in the absence of invading blood-borne cells. 42 In two patients with Rasmussen's encephalitis a significant increase of [ 11 C](R)-PK11195 binding has been detected in the affected cerebral hemisphere compared with the unaffected contralateral hemisphere. 32 Furthermore, the distribution pattern of increased MRI 32 and to other brain abnormalities, such as subependymal gray matter heterotopia, that often coexists in this condition (unpublished data). The extent to which this microglial activation suggests a primary neuroinflammatory disease process or is secondary to neuronal damage caused by the high seizure frequency in these patients, remains to be established.
IMAGING NEUROINFLAMMATION IN DEGENERATIVE DISEASES
There have been consistent observations of activated microglia in primarily noninflammatory neurodegenerative diseases, such (among others) AD and PD. 43 It is experimentally well established that neuronal injury per se, in the absence of any other contributing pathology (such as damage to blood vessels), evokes a rapid, highly localized activation of microglia around the somata of injured neurons and in anatomical projection areas. 
Movement disorders
Microglial activation has been demonstrated in vivo using [
11 C](R)-PK11195 PET in the brains of patients with idiopathic PD 44, 45 and atypical parkinsonism, such as multiple system atrophy, 46 progressive supranuclear palsy, 47 and corticobasalganglionic degeneration. 48 In these conditions, the distribution of [
11 C](R)-PK11195 binding mirrors the spatial pattern of known distinct neuropathologic hallmarks. These studies also revealed marked within-group variation, with a certain degree of overlap between the cases of idiopathic PD and atypical parkinsonism. Although imaging of activated microglia with [
11 C](R)-PK11195 PET does not serve to override an a priori clinical classification, it does provide a generic measurement of disease location and progression that may help to understand the heterogeneity in the clinical presentation of patients with Parkinsonian or other neurodegenerative disorders.
Two recent reports focused on assessing microglial activation in patients with PD with a combined PET study using for the study of dopaminergic nigrostriatal projections. Ouchi et al. 44 found an increase of [ 11 C](R)-PK11195 binding in the midbrain region (encompassing substantia nigra and other structures in this region) in 10 earlystage, drug-naïve PD patients. Furthermore, the level of [ 11 C](R)-PK11195 binding in the midbrain correlated inversely with the loss of dopaminergic nigrostriatal projection in the putamen and positively with the degree of motor disability. They failed to detect any significant increase of [ 11 C](R)-PK11195 binding in the striatum. In contrast, Gerhard et al. 45 found a more widespread spatial pattern of microglial activation in PD patients both at early and late stages of the disease. The discrepancy between the two studies 44, 45 could be due at least in part to methodologic differences, such as the resolution of PET scanner, the kinetic modeling applied to the parametric images, and the type of image analysis performed. The study of Ouchi et al. 44 did not explore and interrogate the parametric [
11 C](R)-PK11195 images for increases of signal in regions outside the midbrain and basal ganglia. Gerhard et al. 45 performed both an ROI analysis, sampling several cortical regions, and a statistical parametric mapping analysis to localize significant mean differences of ligand binding potential at a voxel level. Statistical parametric mapping allows exploratory voxel by voxel group comparison throughout the entire brain volume without requiring a priori hypothesis. The authors in essence confirmed in vivo what is known from neuropathologic studies; 49 namely, that there is widespread microglial activation in the substantia nigra and basal ganglia, but also in cortical association regions (i.e., hippocampus, transentorhinal cortex, cingulated cortex), the same regions that have a high burden of Lewy body pathology in the early stages of the disease. 50 It is important to note that PD is emerging as a multisystem disease with involvement of regions outside the nigrostriatal connections and that a widely distributed tissue pathology is already present in the early clinical phase of the disease. Furthermore, it is important to be aware of differences in the respective patient population when comparing the results of the aforementioned studies. It is possible that differences in the disease severity and, particularly, in the presence and duration of drug therapy may play a role in the different level of Although it could be that this interval time is too short to determine differences in microglial activation, nonetheless it is more likely that the result reflects the time course of neuroinflammation, with a peak in the preclinical or early stages of PD that reaches a plateau with ongoing activation of microglial cells in the following stages. In experimental studies, it has been shown that [ 3 H]PK11195 binding by activated microglia increases rapidly after neuronal injury, but then does not increase any further when transformation of microglia into macrophages occurs, following neuronal cell death. 21 Second, increased microglial activation in the striatum may reflect loss of nigral dopaminergic projections, subtle molecular neuronal changes due to drug therapy effects, and possibly excitotoxicity from hyperactivity of the subthalamic nucleus, rather than direct pathologic involvement.
In a postmortem study, activated microglia have been found in brains of patients with Huntington disease (HD), particularly in regions known to be targeted, such as the striatum, globus pallidus, and frontal cortex. 51 In vivo evidence of increased [
11 C](R)-PK11195 binding in the striatum and cortical regions in symptomatic HD patients compared with healthy controls has been recently published. 52 In that study, 53 However, a minority of the presymptomatic HD gene carriers studied did not exhibit abnormal striatal [ 11 C](R)-PK11195 or [ 11 C]-raclopride binding. It may be that some of these carriers were further away from neuronal dysfunction and disease onset. Nevertheless, the results indicate that microglial activation is an early process in HD pathogenesis and may be present in the HD brain before the onset of symptoms.
Dementia
The process of neurodegeneration in AD is associated with local glial responses. Activated microglia have been found clustered at the site of senile plaques and associated with fibrillar amyloid peptide deposition and dystrophic neuritis, where they play a role in the phagocytosis of amyloid fibrils. 54 Some studies have implied an active role of microglia in the mediation of amyloid toxicity and subsequent secondary tissue damage via release of cytokines and cytotoxic molecules. 55 This observation had led to the hypothesis that a chronic, selfperpetuating neuroinflammatory stimulation of microglia in AD pathology is an important pathogenetic mechanism that may contribute to disease progression. 55 Cagnin et al. 56 showed that it was possible to detect and quantify in vivo microglial activation in the brain of patients with mild to moderate AD using PET with the radioligand [ 11 C](R)-PK11195. The spatial distribution of [ 11 C](R)-PK11195 binding potential matched the known pattern of pathologic changes typical of ADinferior and medium temporal cortex, amygdala, parietal lobule, and posterior cingulate cortex-and mirrored the regional distribution of cerebral hypometabolism detected with [ 18 F]fluorodeoxyglucose ( 18 FDG) PET in individual patients scanned with the two combined PET tracers (FIG. 3) . The spatial pattern and extent of microglial activation in the brain of AD patients was predictive of which cerebral regions would develop more pronounced brain atrophy in the following years as assessed by longitudinal MRI scans.
This suggests that activated microglial cells clustered in areas of ongoing neurodegenerative changes and that the measure of microglial activation using [
11 C](R)-PK11195 PET may be used as a surrogate marker of disease activity. [ 11 C](R)-PK11195 binding was also increased in the brain of a patient with mild cognitive impairment suggesting that microglial activation, like other pathological processes, such as brain amyloid deposition, is an early event starting years before the clinical manifestation becomes apparent.
Immunization against amyloid ␤ 1-42 (A␤) in mice overexpressing amyloid precursor protein has been shown to reverse the amyloid burden in elderly animals and to prevent amyloid deposition in young ones, 57 possibly through the increased clearance by activated microglia and an efflux of amyloid from the brain into the blood stream. The mechanism of amyloid clearance was attributed to an optimized microglial phagocytosis via Fc receptormediated opsonization or phagocytosis. Initial human immunization experiments with an antibody against amyloid have led to variable, in some cases fatal, outcomes for the development of encephalitis. Trials with A␤ vaccinations are ongoing, and PET imaging of activated microglia has potential to contribute to the monitoring of the effectiveness or collateral effects of such neurotherapies.
It is important to remember that microglial activation is not driven by a specific neurodegenerative pathological process, such as the deposition of amyloid fibrils, but instead is triggered by ongoing tissue pathology and neuronal injury irrespective of the primary cause. It is thus not surprising that increased [
11 C](R)-PK11195 binding is also found in non-amyloid-related degenerative dementia, such as frontotemporal lobar degeneration, a disease characterized by intracellular tau-positive or ubiquitin-positive inclusions and neuronal degeneration. 58 In frontotemporal lobar degeneration, increased [ 11 C](R)-PK11195 binding is prominent in frontotemporal regions and basal ganglia, a regional distribution different from that previously reported for AD patients, and overlaps with the distribution of the ensuing brain atrophy.
IMAGING NEUROINFLAMMATION IN STROKE
Experimental PK11195 binding studies have shown expression by blood-derived and microglia-derived brain macrophages in the infarct core and periphery as early as 3 days, reaching maximum levels after ϳ7 days, in various stroke models. 18 60 and later spread beyond this region into the thalamus and neocortex. The later involvement in regions connected by degenerating white matter tracts to the ischemic core, such as the ipsilateral thalamus via the damaged corticothalamic projections, 61 was due to microglial activation occurring along the neuronal pathways expected to develop Wallerian degeneration and may have a role in long-term plasticity and recovery. 
IMAGING NEUROINFLAMMATION IN NEURONAL REMODELING AND NEUROPLASTICITY
Post-herpetic encephalitis
Secondary neuroinflammatory reactions along fiber tracts have been observed after a lesion disconnecting projecting areas, such as the ipsilateral thalamus after a cortical stroke, or the geniculate body after optic neuritis in MS. Such distributed and projected neuroinflammation along neuronal networks can also occur throughout an entire neuronal circuitry, as has been seen subacutely in patients with herpes simplex encephalitis.
Cagnin et al. 39 studied clinically stable patients with unilateral or asymmetric herpes simplex encephalitis between 5 and 8 months after disease onset and conducted serial follow-up [
11 C](R)-PK11195 PET and volumetric MRI over a period of 2 years. Increased [
11 C](R)-PK11195 signals in the cerebral regions most damaged overlapped with those areas that subsequently developed the most marked atrophic changes. Additionally, microglial activation was found widely distributed beyond the recognizable structural damage. In fact, [ 11 C](R)-PK11195 binding was increased also in regions contralateral to the affected site, and in areas spared from structural damage but connected to the lesioned areas through white matter tracts.
In one patient, for example, increased [
11 C](R)-PK11195 binding was present in structurally normal-appearing regions all belonging to the right limbic circuitry and along the superior longitudinal fasciculus and right angular gyrus. That latter observation appeared particularly relevant, because this patient presented with a peculiar cognitive deficit characterized by a decreased ability to recognize facial emotions, a task in which right angular gyrus seemed critically involved. These findings illustrate that focal damage can lead to widespread microglial activation along an entire neural network (limbic structures and associated areas) and that the pattern of glial activation thus closely reflects neuronal function or dysfunction.
Persistent microglial activation can be detected many months after successful antiviral therapy for herpes encephalitis, and its regional distribution predicts which areas may subsequently undergo atrophic changes. It is important to understand the significance of the persistent neuroinflammatory response that occurs in regions directly connected with the primary lesion site and are not accompanied by further clinical impairment such as cognitive or behavioral deterioration in post-herpetic encephalitis.
A persistent inflammatory tissue response does not necessarily imply continued viral activity. Viral products tend to disappear after the first 3 weeks, and often viral genome can not be detected consistently. 62, 63 This might suggest that late increases of [ 11 C](R)-PK11195 signals reflect primarily a delayed neuroinflammatory response to Wallerian-type degeneration of axons and synaptic terminals of the initially damaged neurons. Microglial activation may be involved in long-lasting modifications of the architecture of neuronal network after an acute insult by contributing to neuroplasticity and remodeling of distributed neuronal network. There are suggestions that activated microglia may also support rather neces-sarily hinder neuronal survival by releasing growth factors and taking part in remodeling of synapses, thus actively contributing to brain plasticity.
9,13
Traumatic peripheral nerve injury
Late trans-synaptic microstructural changes are found in the thalamus of limb-amputated primates, where they underlie at least in part the cortical plasticity induced by the lesion. 64 Using [ 11 C](R)-PK11195 PET, long-term trans-synaptic glial responses have been shown in the human thalamus after peripheral nerve injury. 6 In all seven patients with peripheral nerve or spinal root lesions, increased binding of [ 11 C](R)-PK11195 was found in the thalamus contralateral to the side of injury, up to two decades after the lesion. In contrast, one patient with cervical spinal cord injury showed a bilateral and symmetrical increase of [ 11 C](R)-PK11195 binding in both thalami. These findings were not associated with thalamic atrophy or alterations of MRI signal.
The presence of trans-synaptic glial responses of a remote neuronal injury may contribute to the removal of synapses from deafferented neurons, a process called synaptic stripping, thus mediating cortical plasticity. Such persistence of activated microglia may suggest that even in the chronic stages of the post-traumatic recovery process, structural plasticity continues to occur.
NEW PBR LIGANDS FOR PET STUDIES OF MICROGLIAL ACTIVATION
The isoquinoline carboxamide [ 65 Maeda et al., 66 Zhang et al., 67, 68 and Fujimara et al. 69 have extensively described [ 11 C]DAA1106 and fluorinated derivatives in ex vivo binding experiments on rat brain sections and biodistribution studies in mice. PET imaging has also been performed in normal monkeys or healthy patients, but so far no published data from in vivo experiments using DAA1106 and derivatives in disease states have been published. Guylas et al. 70, 71 have investigated [
11 C]vinpocetine using PET, but only in healthy subjects or monkeys, and pharmacologic data indicate that vinpocetine may bind to binding sites other than the PBR. Belloli et al. 72 have evaluated carbon-11 labeled VC193M, VC195, and VC198M in a rat model of striatal damage (quinolinic acid), and their in vivo distribution by microdissection of the brain. In these experiments, similar results were obtained when using either PK11195 or VC195. More recently the pyrazolopyrimidines have emerged as exciting new molecular probes for the PBR, with DPA-713 representing one of the lead members; 73 however, further evaluation in humans is still required to determine their clinical utility.
SUMMARY
PBR ligands, such as [
11 C](R)-PK11195 that bind with relative cellular selectivity to activated microglia can be used to 1) detect in vivo neuroinflammatory changes occurring in a variety of brain diseases and at different disease stages;
2) monitor the progression of neuroinflammation as a generic in vivo marker of disease activity; and 3) detect cellular responses in areas remote from the primary lesion site that may be involved in axonal Wallerian degeneration and neuronal remodeling.
The use of [ 11 C](R)-PK11195 PET is a systematic attempt at measuring the emerging phenomenology tissue pathology itself-as opposed to measuring, for example, the loss of neuronal function or structure. Although methodologic issues, such as sensitivity or absolute quantification of the specific ligand, remain, 
